David R Boulware, Christopher J Lindsell, Thomas G Stewart, Adrian F Hernandez, Sean Collins, Matthew William McCarthy, Dushyantha Jayaweera, Nina Gentile, Mario Castro, Mark Sulkowski, Kathleen McTigue, G Michael Felker, Adit A Ginde, Sarah E Dunsmore, Stacey J Adam, Allison DeLong, George Hanna, April Remaly, Florence Thicklin, Rhonda Wilder, Sybil Wilson, Elizabeth Shenkman, Susanna Naggie
BACKGROUND: The effectiveness of inhaled glucocorticoids in shortening the time to symptom resolution or preventing hospitalization or death among outpatients with mild-to-moderate coronavirus disease 2019 (Covid-19) is unclear. METHODS: We conducted a decentralized, double-blind, randomized, placebo-controlled platform trial in the United States to assess the use of repurposed medications in outpatients with confirmed coronavirus disease 2019 (Covid-19). Nonhospitalized adults 30 years of age or older who had at least two symptoms of acute infection that had been present for no more than 7 days before enrollment were randomly assigned to receive inhaled fluticasone furoate at a dose of 200 μg once daily for 14 days or placebo...
September 21, 2023: New England Journal of Medicine